Generating Developable 3D Molecules via Pocket-Conditioned Diffusion and Property-Aware Optimization

📅 2026-07-14
📈 Citations: 0
Influential: 0
📄 PDF
🤖 AI Summary
This work addresses the challenge in structure-based drug design where existing diffusion models struggle to simultaneously optimize target binding affinity and molecular developability, particularly ADMET properties. The authors propose conDitar-dev, a novel framework that decouples pocket and ligand representations and integrates multi-scale pocket encoding (msPRL), pocket-conditioned diffusion generation (conDitar), and a property-aware optimization strategy (paOPT) to enable atomic- and molecular-level co-modeling with real-time ADMET optimization during generation. Evaluated on human disease targets, the method achieves an average binding energy of −8.85 kcal/mol and improves ADMET performance by up to 73%. Experimentally validated molecules targeting PD-L1 and CSF1R demonstrate micromolar binding affinity and nanomolar inhibitory activity.
📝 Abstract
Drug discovery and development is time-consuming and resource-intensive, motivating computational approaches such as diffusion models for de novo drug design. Many such models follow the structure-based drug design (SBDD) paradigm, generating molecules to fit a target binding pocket. However, existing diffusion-based SBDD methods typically couple pocket and ligand representation learning, model interactions only at the atom level, and prioritize binding affinity over other developability properties. Here, we introduce conDitar-dev, a conditional diffusion-based SBDD framework for generating ligands with strong binding affinities and favorable ADMET properties. It consists of three modules: msPRL, a pretrained multi-scale pocket representation learning module; conDitar, a pocket-conditioned diffusion model guided by msPRL representations; and paOPT, a generation-time method for optimizing ligand developability. On a newly curated benchmark of human disease targets, conDitar outperforms state-of-the-art SBDD baselines, achieving an average binding score of -8.85 kcal/mol. Across five ADMET properties, conDitar-dev improves performance by up to 73% over conDitar. To further validate the abilities of conDitar-dev to generate developable molecules, we have applied it to two validated druggable targets: programmed death-ligand 1 (PD-L1) and colony-stimulating factor 1 receptor (CSF1R) proteins. Top-ranked generatively designed molecules and their analogs have been experimentally synthesized and biologically tested. Two molecules generated directly by conDitar-dev for PD-L1 exhibited SPR-derived $K_D$ values of 3.49 and 3.75 $μ$M, respectively. Hit expansion based on conDitar-dev-designed molecules identified selective CSF1R inhibitors with IC$_{50}$ values as low as 200 nM, while also uncovering opportunities for drug repositioning.
Problem

Research questions and friction points this paper is trying to address.

drug developability
structure-based drug design
ADMET properties
binding affinity
molecular generation
Innovation

Methods, ideas, or system contributions that make the work stand out.

pocket-conditioned diffusion
multi-scale pocket representation
property-aware optimization
developable molecule generation
structure-based drug design
🔎 Similar Papers
No similar papers found.
💼 Related Jobs
Postdoctoral Fellow – AI-Driven Multi-Omics Integration for Predictive Toxicology
Pfizer
The annual base salary for this position ranges from $64,600.00 to $107,600.00. In addition, this position is eligible for participation in Pfizer’s Global Performance Plan with a bonus target of 7.5% of the base salary. We offer comprehensive and generous benefits and programs to help our colleagues lead healthy lives and to support each of life’s moments. Benefits offered include a 401(k) plan with Pfizer Matching Contributions and an additional Pfizer Retirement Savings Contribution, paid vacation, holiday and personal days, paid caregiver/parental and medical leave, and health benefits to include medical, prescription drug, dental and vision coverage. Learn more at Pfizer Candidate Site – U.S. Benefits | (uscandidates.mypfizerbenefits.com). Pfizer compensation structures and benefit packages are aligned based on the location of hire. The United States salary range provided does not apply to Tampa, FL or any location outside of the United States. Relocation assistance may be available based on business needs and/or eligibility.
Hybrid
R
Ruoxi Gao
Computer Science and Engineering, The Ohio State University, Columbus, OH 43210.
J
Jiangweizhi Peng
Industrial and System Engineering, University of Minnesota, Minneapolis, MN 55455.
Ziqi Chen
Ziqi Chen
Google
Deep LearningGenerative Models
F
Frazier N. Baker
Computer Science and Engineering, The Ohio State University, Columbus, OH 43210.
D
David C. Kombo
Medicinal Chemistry Department, Integrated Drug Discovery, Sanofi, Cambridge, MA 02141.
J
John L. Kane Jr.
Medicinal Chemistry Department, Integrated Drug Discovery, Sanofi, Cambridge, MA 02141.
A
Andrew A. Scholte
Medicinal Chemistry Department, Integrated Drug Discovery, Sanofi, Cambridge, MA 02141.
Y
Yi Li
Medicinal Chemistry Department, Integrated Drug Discovery, Sanofi, Cambridge, MA 02141.
M
Matthew J. LaMarche
Medicinal Chemistry Department, Integrated Drug Discovery, Sanofi, Cambridge, MA 02141.
L
Luigi I. Iconaru
In-Vitro Biology Department, Integrated Drug Discovery, Sanofi, Cambridge, MA 02141.
H
Hans-Peter Biemann
In-Vitro Biology Department, Integrated Drug Discovery, Sanofi, Cambridge, MA 02141.
Mingyi Hong
Mingyi Hong
Associate Professor, University of Minnesota; Amazon AGI
Machine LearningOptimizationGenerative AISignal processing
Xia Ning
Xia Ning
Professor, Biomedical Informatics, Computer Science and Engineering, The Ohio State
GenAIMedical AILLMsDrug Development